LCGC North America
What are the characteristics and relevant considerations for the development and validation of a stability-indicating method?
Arindam Roy
Advertisement
Articles by Arindam Roy
LCGC Europe
In the pharmaceutical industry, the demonstration of drug substance (DS) or drug product (DP) stability over the shelf life is an important aspect of the regulatory requirements.
![Roy figure 5-[41827930]-{585410}-746304-1416911904998.gif](https://cdn.sanity.io/images/0vv8moc6/chroma/5e8a7a8b42be4c1287e42a9e19c61a898804cfe5-700x592.gif?w=350&fit=crop&auto=format)
Special Issues
A discussion of active pharmaceutical ingredient (API) selection, drug product development, and mass spectrometry instrumentation
Advertisement
Latest Updated Articles
![Roy figure 5-[41827930]-{585410}-746304-1416911904998.gif](https://cdn.sanity.io/images/0vv8moc6/chroma/5e8a7a8b42be4c1287e42a9e19c61a898804cfe5-700x592.gif?w=300&fit=crop&auto=format)
Advertisement
Advertisement
Trending on LCGC International
1
How AI and Machine Learning Are Reshaping Separations Science at HPLC 2026
2
Chromatographic and Mass Spectrometric Screening of Novel Psychoactive Substances in Seized Drug Analysis
3
Industry Roundup: Bruker Unveils Next-Generation Multiomics MS Tools at ASMS
4
HPLC Comparison of Dopamine in Parkinson's Therapy
5